![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
SUVN-G3031 (samelisant), potent and selective histamine H3 receptor inverse agonist, is being developed for the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy.
Lead Product(s): Samelisant
Therapeutic Area: Sleep Product Name: SUVN-G3031
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024